AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3265525 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 5 mg diazepam
Number of subjects: 90
Study 1887747 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with orotracheal intubation
Number of subjects: 40
Study 1887747 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscopy without orotracheal intubation
Number of subjects: 40
Study 332196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloalliin, single oral dosage
Number of subjects: 18
Study 332196 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18
Study 30278197 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Laser Trabeculoplasty (SLT)
Number of subjects: 130
Study 30278197 — intervention group
Group type: COMPARATOR
Intervention: Argon Laser Trabeculoplasty (ALT)
Number of subjects: 130
Study 28199736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCP)
Number of subjects: 87
Study 28199736 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle (intensive Lifestyle modification)
Number of subjects: 87
Study 28199736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (OCP + Lifestyle)
Number of subjects: 87
Study 28199736 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP
Number of subjects: 87
Study 28199736 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle and Combined groups
Number of subjects: 87
Study 25675384 — intervention group
Group type: EXPERIMENTAL
Intervention: RM-493 (1 mg/24 h)
Number of subjects: 12
Study 25675384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24015415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 90
Study 24015415 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 90
Study 22397264 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplement containing D‐phenylalanine, L‐glutamine and L‐5‐hydroxytriptophan
Number of subjects: 20
Study 22397264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19715914 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus with Cyclosporine and Steroids (SRL-CsA-ST)
Number of subjects: 525
Study 19715914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus with Steroids after Cyclosporine withdrawal (SRL-ST)
Number of subjects: 525
Study 19715914 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SRL-CsA-ST and SRL-ST)
Number of subjects: 525
Study 19715914 — intervention group
Group type: COMPARATOR
Intervention: SRL-CsA-ST
Number of subjects: 525
Study 19715914 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL-ST
Number of subjects: 525
Study 18236765 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei simiaosan combined with the external application of Sihuangshuimi
Number of subjects: 65
Study 18236765 — intervention group
Group type: COMPARATOR
Intervention: Gout treatment with colchicine
Number of subjects: 65
Study 14685854 — intervention group
Group type: EXPERIMENTAL
Intervention: Contiguity and contingency manipulation of key presses and subsequent tones
Number of subjects: 0
Study 11581559 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (ET) group performed 30 repetitions of maximal voluntary isokinetic eccentric contraction (ECC1) on nondominant elbow flexors with Cybex 6000 at 60 degrees.s‐1 angular velocity for 7 consecutive days (ECC2 to ECC7).
Number of subjects: 22
Study 11581559 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) did not perform the eccentric training.
Number of subjects: 22
Study 9886905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg daily
Number of subjects: 6450
Study 9886905 — intervention group
Group type: COMPARATOR
Intervention: Co-amilozide (hydrochlorothiazide 25 mg/amiloride 5 mg) once daily
Number of subjects: 6450
Study 8057222 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Zn++ as sulfate daily
Number of subjects: 200
Study 8057222 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Zn++ as sulfate daily
Number of subjects: 200
Study 8057222 — intervention group
Group type: COMPARATOR
Intervention: 0 mg Zn++ as sulfate daily (control)
Number of subjects: 200
Study 8057222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low zinc intake (about one-tenth of RDA)
Number of subjects: 200
Study 8057222 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with highest rates of growth
Number of subjects: 200
Study 2736749 — intervention group
Group type: EXPERIMENTAL
Intervention: Early angiography (17 +/- 6 hours)
Number of subjects: 78
Study 2736749 — intervention group
Group type: COMPARATOR
Intervention: Late angiography (5.7 +/- 2.1 days)
Number of subjects: 78
Study 2736749 — intervention group
Group type: COMPARATOR
Intervention: Late elective angiography
Number of subjects: 78
Study 2736749 — intervention group
Group type: COMPARATOR
Intervention: Late urgent angiography
Number of subjects: 78
Study 2736749 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with coronary thrombus
Number of subjects: 78
Study 2736749 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with complex coronary morphology
Number of subjects: 78
Study 2736749 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with multiple-vessel disease
Number of subjects: 78
Study 2736749 — intervention group
Group type: COMPARATOR
Intervention: Patients without angiographic features
Number of subjects: 78
Study 2736749 — intervention group
Group type: COMPARATOR
Intervention: Patients without complex coronary morphology
Number of subjects: 78
Study 2736749 — intervention group
Group type: COMPARATOR
Intervention: Patients without multiple-vessel disease
Number of subjects: 78
Study 31147827 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step etch-and-rinse (3-ER)
Number of subjects: 39
Study 31147827 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse (2-ER)
Number of subjects: 39
Study 31147827 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etch (2-SE)
Number of subjects: 39
Study 31147827 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etch (1-SE)
Number of subjects: 39
Study 29688617 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib extended-release (ER) formulation 15 mg once daily
Number of subjects: 0
Study 29688617 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib extended-release (ER) formulation 30 mg once daily
Number of subjects: 0
Study 29688617 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib extended-release (ER) formulation
Number of subjects: 0
Study 29688617 — intervention group
Group type: COMPARATOR
Intervention: High-fat breakfast
Number of subjects: 0
Study 27100393 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil or nuts
Number of subjects: 1139
Study 27100393 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 1139
Study 27100393 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing urinary TPE
Number of subjects: 1139
Study 26208685 — intervention group
Group type: EXPERIMENTAL
Intervention: Abluminal groove-filled biodegradable polymer sirolimus-eluting stent (SES)
Number of subjects: 458
Study 26208685 — intervention group
Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stent (EES)
Number of subjects: 458
Study 24298784 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 157
Study 24298784 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture
Number of subjects: 157
Study 22900449 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomized administration of intranasal ketamine (INK)
Number of subjects: 34
Study 22900449 — intervention group
Group type: COMPARATOR
Intervention: Drops administration of intranasal ketamine (INK)
Number of subjects: 34
Study 19455040 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 2.0 mg/kg
Number of subjects: 116
Study 19455040 — intervention group
Group type: EXPERIMENTAL
Intervention: sugammadex 4.0 mg/kg
Number of subjects: 116
Study 19455040 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 116
Study 16477334 — intervention group
Group type: EXPERIMENTAL
Intervention: Gow-Gates mandibular block (GGMB)
Number of subjects: 162
Study 16477334 — intervention group
Group type: COMPARATOR
Intervention: Inferior alveolar nerve block (IANB)
Number of subjects: 162
Study 14629843 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 98
Study 12118835 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO+)
Number of subjects: 20
Study 12118835 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO-)
Number of subjects: 20
Study 12118835 — intervention group
Group type: COMPARATOR
Intervention: EPO-
Number of subjects: 20
Study 12118835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) using H and PS membranes
Number of subjects: 20
Study 12118835 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO+ and EPO-
Number of subjects: 20
Study 9361169 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocloprost
Number of subjects: 40
Study 9361169 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 40
Study 1557484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 30
Study 1557484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3901650 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 216
Study 3901650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 31111798 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive-behavioural therapy
Number of subjects: 0
Study 31111798 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 30115826 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain rye kernel-based bread (RKB)
Number of subjects: 0
Study 30115826 — intervention group
Group type: COMPARATOR
Intervention: White wheat flour-based bread (WWB)
Number of subjects: 0
Study 27132053 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy
Number of subjects: 702
Study 27132053 — intervention group
Group type: COMPARATOR
Intervention: No hysteroscopy (control group)
Number of subjects: 702
Study 25716546 — intervention group
Group type: EXPERIMENTAL
Intervention: TOF group (targeted to maintain two counts of train‐of‐four (TOF))
Number of subjects: 0
Study 25716546 — intervention group
Group type: EXPERIMENTAL
Intervention: T1 group (maintain the T1/Tc ratio at 50%)
Number of subjects: 0
Study 25716546 — intervention group
Group type: COMPARATOR
Intervention: N group (no relaxants after tracheal intubation)
Number of subjects: 0
Study 22762867 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of tobramycin inhalation solution (TIS) for 28 days
Number of subjects: 58
Study 22762867 — intervention group
Group type: COMPARATOR
Intervention: Inhaled sodium colistimethate (2×2 millU/day) plus oral ciprofloxacin (30 mg/kg/day) for 3 months (CC)
Number of subjects: 58
Study 22762867 — intervention group
Group type: COMPARATOR
Intervention: Inhaled sodium colistimethate (CC) for 3 months
Number of subjects: 58
Study 22762867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (TIS and CC)
Number of subjects: 58
Study 20304396 — intervention group
Group type: EXPERIMENTAL
Intervention: DJBL
Number of subjects: 47
Study 20304396 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 47
Study 18978107 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 364
Study 18978107 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 364
Study 15671222 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake (dietary and supplemental)
Number of subjects: 1905
Study 15671222 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake (dietary and supplemental)
Number of subjects: 1905
Study 15671222 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental calcium and vitamin D use during follow-up
Number of subjects: 1905
Study 12662005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol
Number of subjects: 106
Study 12662005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin, ethambutol and isoniazid
Number of subjects: 106
Study 12662005 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 106
Study 10485302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber syringe (n = 213)
Number of subjects: 487
Study 10485302 — intervention group
Group type: COMPARATOR
Intervention: Separate injections (n = 215)
Number of subjects: 487
Study 10485302 — intervention group
Group type: COMPARATOR
Intervention: Single manually reconstituted injection (n = 59)
Number of subjects: 487
Study 10485302 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (PRP-T and DTP-IPV)
Number of subjects: 487
Study 10485302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber syringe and separate injection methods
Number of subjects: 487
Study 8602666 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (5, 10, 20, and 50 micrograms x kg(‐1))
Number of subjects: 108
Study 8602666 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (100, 200, 400, and 1,000 micrograms x kg(‐1))
Number of subjects: 108
Study 8602666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 8602666 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous recovery
Number of subjects: 108
Study 2016625 — intervention group
Group type: EXPERIMENTAL
Intervention: FAMTX (methotrexate, fluorouracil, doxorubicin)
Number of subjects: 213
Study 2016625 — intervention group
Group type: COMPARATOR
Intervention: FAM (fluorouracil, doxorubicin, mitomycin)
Number of subjects: 213
Study 7006539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (Motrin)
Number of subjects: 15
Study 31870658 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue protocol
Number of subjects: 40
Study 31870658 — intervention group
Group type: COMPARATOR
Intervention: Sham fatigue protocol
Number of subjects: 40
Study 31060834 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meals with 11 ml extra virgin olive oil
Number of subjects: 20
Study 31060834 — intervention group
Group type: COMPARATOR
Intervention: Mixed meals without extra virgin olive oil
Number of subjects: 20
Study 27911049 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week special intervention (SI)
Number of subjects: 108
Study 27911049 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (DI)
Number of subjects: 108
Study 26431847 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-Based Medicine (EBM) program including a roundtable seminar on Depot Medroxy Progesterone Acetate (DMPA) and two 15 min one-on-one educational visits.
Number of subjects: 0
Study 26431847 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified, but implied as those not receiving the EBM program.
Number of subjects: 0
Study 24131872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet consultation
Number of subjects: 326
Study 24131872 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 326
Study 21204827 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 600 mg
Number of subjects: 25
Study 21204827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21204827 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 25
Study 18075754 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype firefighter ensemble (PE) in dry conditions
Number of subjects: 8
Study 18075754 — intervention group
Group type: COMPARATOR
Intervention: Standard ensemble (SE) in dry conditions
Number of subjects: 8
Study 18075754 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype firefighter ensemble (PE) in wet conditions
Number of subjects: 8
Study 18075754 — intervention group
Group type: COMPARATOR
Intervention: Standard ensemble (SE) in wet conditions
Number of subjects: 8
Study 17062050 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% FFS
Number of subjects: 273
Study 17062050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 12965315 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic T3‐4 sympathicotomy
Number of subjects: 262
Study 11196420 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/d)
Number of subjects: 24
Study 11196420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1541612 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (12 immediate and 3 delayed)
Number of subjects: 24
Study 1541612 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory medications
Number of subjects: 24
Study 3895963 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg single-dose treatment
Number of subjects: 103
Study 3895963 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 200 mg 3-day treatment
Number of subjects: 103
Study 30707661 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg two times per day (days 1 to 7; 21-day cycle)
Number of subjects: 271
Study 30707661 — intervention group
Group type: COMPARATOR
Intervention: Investigator-selected single-agent comparator (including intravenous pralatrexate 30 mg/m2 once per week for 6 weeks; intravenous gemcitabine 1,000 mg/m2; or intravenous romidepsin 14 mg/m2 days 1, 8, and 15; 28-day cycle)
Number of subjects: 271
Study 30707661 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib
Number of subjects: 271
Study 30707661 — intervention group
Group type: COMPARATOR
Intervention: Comparator
Number of subjects: 271
Study 29223355 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 32
Study 29223355 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32
Study 26012547 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroscopy
Number of subjects: 4096
Study 26012547 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiological assessment
Number of subjects: 4096
Study 23406475 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive norm
Number of subjects: 96
Study 23406475 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norm
Number of subjects: 96
Study 23406475 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 22356118 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy (5-20 mg/day)
Number of subjects: 139
Study 22356118 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine with mood stabilizer (lithium, carbamazepine, or valproate)
Number of subjects: 139
Study 20585710 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Robert‐Jones bandage for 24 hours
Number of subjects: 2
Study 20585710 — intervention group
Group type: COMPARATOR
Intervention: No bandage (Control)
Number of subjects: 2
Study 18339043 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear lubricant (Refresh Soothe and Protect)
Number of subjects: 18
Study 18339043 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline (Chauvin Pharmaceuticals Ltd)
Number of subjects: 18
Study 18339043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional eye drops)
Number of subjects: 18
Study 15750379 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 11796654 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 21
Study 11796654 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 21
Study 11796654 — intervention group
Group type: COMPARATOR
Intervention: Boys vs. Men
Number of subjects: 21
Study 10595868 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine-containing triple therapies
Number of subjects: 0
Study 10595868 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine-containing combination therapies
Number of subjects: 0
Study 10595868 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine
Number of subjects: 0
Study 8706777 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine 200 mg given 2 hours before codeine
Number of subjects: 17
Study 8706777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no quinidine)
Number of subjects: 17
Study 8706777 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine 200 mg
Number of subjects: 17
Study 8706777 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine pre-treatment
Number of subjects: 17
Study 1535302 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day)
Number of subjects: 16
Study 1535302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6380205 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine (Bisolvon) 48 mg daily for 3 weeks
Number of subjects: 32
Study 6380205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31603721 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 115
Study 31603721 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (Control)
Number of subjects: 115
Study 29186529 — intervention group
Group type: EXPERIMENTAL
Intervention: DAV132 coadministration with moxifloxacin
Number of subjects: 28
Study 29186529 — intervention group
Group type: COMPARATOR
Intervention: DAV132 alone
Number of subjects: 28
Study 29186529 — intervention group
Group type: COMPARATOR
Intervention: Nonactive substitute
Number of subjects: 28
Study 26843120 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng (5 g daily for 12 weeks)
Number of subjects: 62
Study 25259743 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 μg/d for 12 weeks)
Number of subjects: 88
Study 25259743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 25259743 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 88
Study 22187085 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 26
Study 22187085 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 26
Study 22187085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Prone and Supine)
Number of subjects: 26